Mylan Announces Acquisition of U.S. Rights to Zagam.

PITTSBURGH--(BUSINESS WIRE)--August 26, 1998--Mylan Laboratories Inc. (NYSE:MYL) announced today that it has acquired from Rhone-Poulenc Roret Pharmaceuticals Inc., the exclusive U.S. rights to manufacture and market Zagam(R) (Sparfloxacin).

The product is licensed from Dainippon Pharmaceutical Co. Ltd.

Zagam(R) is a patent protected antimicrobial agent for oral administration used to treat lower respiratory infections. Zagam(R) is indicated for the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis.

Zagam(R) will be promoted and detailed through Mylan's branded subsidiary Bertek Pharmaceuticals Inc. The Bertek sales force will add Zagam(R) to its current product portfolio which includes Maxzide(R), a once-a-day triamterene hydrochlorothiazide diuretic, Nitrek(R), a nitroglycerin transdermal patch system, and Clorpres(TM), a combination of clonidine hydrochloride and chlorthalidone. In addition, through its co-promotions with Penederm, Incorporated, Bertek also promotes Mentax(R), a prescription topical antifungal product and Avita(R), a topical retinoic acid product.

Milan Puskar, Chairman, CEO and President of Mylan Laboratories Inc., stated that "the acquisition of Zagam(R) demonstrates our continued commitment to establishing Bertek Pharmaceuticals as a major branded pharmaceutical company. We are continuing to look for additional branded products to add to the Bertek line."

Bill Richardson, President of Bertek Pharmaceuticals Inc., stated that "we are excited to add Zagam(R) to our current line of products." Richardson further stated "Zagam(R) will provide opportunities in the primary care markets and in the institutional and managed care markets, as well."

CONTACT: Mylan Laboratories Inc., Pittsburgh

Patricia Sunseri, 412/232-0100